Topic: venture capital (VC)
The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.
The fund sets Frazier up to place another set of bets spanning from company creation through public investments.
A new $100 million (€85 million) capital fund out of Germany has closed and is looking for “ground-breaking” heart disease tech.
Concerto HealthAI unveiled a steady drum beat of announcements at this year’s J.P. Morgan Healthcare Conference, including a $150 million raise.
Emendo has worked to expand the list of diseases amenable to treatment with gene editing, resulting in hematology and ophthalmology programs.
Alexis Borisy is leading a new kind of biotech company that will “reshape the industry” by introducing new medicines at “radically lower” prices.
Virtual Incision raised $20 million for the development of its miniaturized surgical robot to help support its regulatory and clinical programs.
Tyra Biosciences raised $50 million to develop a pipeline of “very specific” small molecules to target drug-resistant cancer cells.
The financing, which could grow by another $1.2 billion, sets Blackstone up to continue placing bets such as its ventures with Novartis and Ferring.
In 2018, Generation Bio broke cover with a $25 million series A, swiftly followed by a meatier $100 million second funding round.